drugset / Trial / NCT02084485

PH-797804 LPS Study in Healthy Volunteers

NCT02084485

Phase 1 Completed 24 enrolled Pfizer
RandomizedCrossoverDouble-blindBasic science

Summary

The study was performed to assess the effect of PH-797804 on neutrophils (white cells) in the sputum after a challenge with an endotoxin (inhaled LPS). Neutrophils are a sign of inflammation and PH-797804 is being developed as a potential anti-inflammatory treatment for patients with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start
2006-09
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject PH-797804 Small molecule 30 mg Oral

Indications

No indication recorded.